TATAA-DEVELOPED TECHNOLOGIES
Experience drives innovation
TATAA’s essence is that problem-solving builds experience, and experience accelerates problem-solving, leading to innovations and pioneering technologies. This approach has brought us to where we are today, enabling us to offer our customers exceptional solutions.
HISTORY OF INNOVATION
TATAA Biocenter has a history of innovations
As one of the 24 expert organizations co-authoring the publication “Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development,” published in AAPS in 2024, we advance and shape the field of PCR bioanalysis.
With various solutions to optimize extraction and assay design, we often succeed where others fail. Pioneering the field of bioanalysis for short test items like siRNA, miRNA, and ASOs, we have invented the Two-Tailed PCR technology.
Reveal true performance with TATAA controls
We have developed our own control assays for crucial performance indicators, including extraction efficiency, primer and probe performance, target degradation, interplate variations, and inhibition in either the RT step or the qPCR/dPCR.
Two-Tailed PCR
Accelerate with unique PCR technology for short test items
Short nucleic acids such as siRNA, miRNA, and ASO are way too short to be targeted by the two conventional primers required for PCR. Current methods, therefore, extend short nucleic acid targets by some means prior to amplification. This, however, compromises the sensitivity and specificity of the assay. TATAA has found a solution.
In Two-Tailed PCR, a single molecule designed with a hairpin structure hybridizes to the target with two interaction sites. Each site alone is too short to bind, but the double interaction provides greater sensitivity and superior specificity as part of the same molecule.
Direct Blood Genotyping (DBG)
Genetic testing is typically performed on venous blood samples collected at the Doctor’s office and sent to a central laboratory that extracts and analyses the DNA. Results are sent to the Doctor, who prescribes drugs and treatment to their patient based on the results. TATAA’s Direct Blood Genotyping (“DBG”) allows genetic testing to be performed at the Point of Care at the Doctor’s office with no extraction needed. Furthermore, capillary blood is sufficient, making the entire process simple and convenient.
Immunosequencing entails the high-throughput sequencing of T-cell (TCR) and B-cell receptors (BCR), offering invaluable insights into the immune response within CAR-T therapies. Download the blog as PDF. T-cell malignancies following CAR-T therapy There is a potential risk of secondary cancers
Small RNAs, such as siRNA, miRNA, snoRNA, and others ranging from approximately 18 to 26 nucleotides, cannot be amplified using conventional PCR primers, as a single primer matches their entire length. Various techniques are used to elongate short RNA molecules
